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Abstract  
Neurotensin receptor-3 or sortilin is a vacuolar protein sorting 10 protein domain (Vps10p) has 
been firstly discovered in the human brain, it acts as receptor or co-receptor of the cell and 
traffics different proteins within the cell. Sortilin deregulation contributes to the development 
of several diseases, including neurological diseases and cancer. On the other hand, 
neurotrophins which are a family of proteins essential for the nervous system development, 
function and plasticity. The first discovered member is the nerve growth factor; other members 
are brain-derived growth factor, neurotrophin-3 and neurotrophin-4. Nerve growth factor and 
brain-derived growth factor are the common neurotrophins that have a role in cancer. 
Neurotrophins initiate their signals through interaction with tyrosine receptor kinases TrkA, 
TrkB, and TrkC; each member has an affinity for a specific receptor to stimulate cell survival, 
while the interaction with p75NTR initiates cell apoptosis pathway by forming a complex with 
sortilin and neurotrophin precursors. A number of therapeutic approaches are emerging to 
target the neurotrophins pathway as well as sortilin.  
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Abbreviations:  
AKT, RAC-alpha serine/threonine-protein kinase ;BDNF, brain-derived growth factor; ER, 
endoplasmic reticulum;  ERK, extracellular signal-regulated kinase; GLUT4, glucose 
transporter type 4; GWAS, Genome-Wide Association Study;  MAPK, mitogen activated 
protein kinase; NGF, Nerve growth factor; NSCLC, non-small cell lung cancer;  NT, 
neurotensin; NT-3, neurotrophin-3;  NT-4, neurotrophin-4;  PI3K, phosphatidylinositol 3-
kinase;  PLC-γ1, phospholipase C-γ1;  SCLC- small cell lung cancer; TGN, trans Golgi 
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Introduction 
Sortilin, also known as neurotensin receptor 3, is a member of vacuolar protein sorting 10 
protein (Vps10p) domain family, which was first discovered in the human brain, but it is also 
expressed in many tissues [1]. Sortilin is encoded by SORT1 gene, located on chromosome 
1p13.3. Sortilin acts as a receptor or co-receptor responsible for cell survival, signal 
transduction, and sorting or trafficking proteins such as neurotrophins to the plasma membrane, 
lysosomes or endocytic pathway [2, 3]. Neurotrophins compose a protein family that are 
important for the nervous system development, function and plasticity. They exert their 
functions either by interacting with the tyrosine kinase receptors (Trks) to induce different 
pathways such as Rat Sarcoma (Ras), phosphatidylinositol 3-kinase (PI3K), and phospholipase 
C-γ1 (PLC-γ1) responsible for cell survival [4] or with p75 NTR neurotrophin receptor to induce 
activation of NF-κB and Jun N-terminal kinase (JNK) and modulates RhoA activity that ends 
up with cell apoptosis or survival [5]. Sortilin forms a heteromeric complex with p75NTR at the 
cell surface that transduces the pro-neurotrophin cell death signals, while with Trks, sortilin 
enhances neurotrophins signals by facilitating the anterograde transport along axons. 
Therefore, the defect of sortilin expression in many human cell lines might affect neurotrophins 
trafficking and release [6]. Hence, the imbalance of neurotrophin signalling has been involved 
in various diseases, such as Alzheimer’s disease (AD), Parkinson’s disease (PD), 
cardiovascular disease (CVD), type II diabetes mellitus (T2 DM), as well as cancer. In AD, 
sortilin mediates the trafficking of b-secretase, thus increasing the beta-amyloid precursor 
protein cleavage [7], while in diabetes formation of GLUT-4 storage vesicles are affected by 
sortilin expression [8]. In CVDs, sortilin correlates with the levels of circulatory low-density 
lipoprotein, in addition to SNPs located on chromosome 1p13.3 that associated with sortilin 
and cardiovascular phenotypes [9]. Sortilin expression is elevated in many types of carcinomas, 
along with alteration in Trks expression [8]. Herein, we discuss the effect of sortilin 
dysregulation in neurotrophins trafficking, their role in developing of various diseases, and the 
ongoing therapeutic applications that target sortilin and neurotrophin receptors. 
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Sortilin family, structure and function 
In 1997, Petersen and colleagues discovered sortilin by receptor-associated protein affinity 
chromatography through isolation, identification and purification of membrane glycoprotein 
(95kDa), this protein was initially called gp95 and later named as sortilin (also known as 
neurotensin receptor 3). After cDNA cloning and screening, the receptor structure and the 
sequence homologies with vacuolar sorting protein 10 protein domain (Vps10p) was identified 
[1, 10]. Sortilin is a 100kDa type-1 membrane glycoprotein which belongs to the Vps10p 
receptor family. The Vps10 protein family include heterogenous type-1 transmembrane 
receptors, which consists of sortilin (100 kDa), SorLA, SorCS1, SorCS2, and SorCS3 [11]. 
The pre-fix “sor” is used as an abbreviation for the names of Vps10 family members “sorting 
receptor-related” [12]. It consists of two domains; the large segment is named the extracellular 
domain, while the short tail is the cytoplasmic or intracellular domain [1]. The extracellular 
domain contains Vps10p domain, which in turn consists of structural domains. The first 
structure is known as a ten bladed β-propeller which situated in the N-terminal domain, 
followed by two small domains, 10CC-a and 10CC-b which represents the ten conserved 
cysteines (10CC) in the C-terminal segment. Both 10CC-a and 10CC-b interact extensively 
with the β-propeller [13]. 
Several studies demonstrated that the sortilin family are synthesised as a precursor at the ER 
and then converted to the mature form at the trans-Golgi network (TGN) through the removal 
of the N-terminal preprotein that contains convertase consensus cleavage sequence (RXXR). 
This cleavage opens the structure of sortilin by exposing a ligand-binding region [2, 14]; 
additional motif found in the N-terminal domain is Fibronectin-type III which shows different 
function between Vps10p members [11]. However, the β-propeller consists of ten blades in a 
wheel-shape with a conical tunnel that contains a ligand-binding site, with a diameter of 25 by 
37 Å in the cross-section. Each blade has a four-stranded β-sheet stabilised by an Asp-box 
repeat, which is a short repeat motif between strands 3 and 4 to support the structural integrity 
in β-propellers [13]. 
While the cytoplasmic domain contains motifs established from several signal sequences to be 
involved in binding to adaptor proteins including (AP-1, AP-2), Golgi-localised, γ ear-
containing, ADP ribosylation factors (ARF) -binding proteins (GGA1, GGA2 and GGA3), [15, 
16], Ras-related protein (Rab7b) and phosphofurin acidic cluster-sorting protein 1 (PACS-1). 
The well-defined sorting sites in sortilin are C-terminal acidic cluster combined with dileucine 
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which targeted by AP-1, -2, GGA proteins and PACS-1 and involved in Golgi-endosome 
trafficking; and the second site is tyrosine-based motif that located at the upper third of the 
cytoplasmic part, contributes to endocytosis through AP-2 binding and also could participate 
in the trafficking pathway between Golgi and endosome by AP-1, in addition to its binding to 
p21 activated kinases (PAK 1-3) that have an effect on neuronal and non-neuronal cells growth, 
shape and motility [17]. Also, sortilin shares similarity to the mannose-6 phosphate receptor; 
thereby, sortilin could guide lysosomal enzymes from TGN to endosomes and lysosomes [18]. 
Sortilin plays a role in the delivery of sphingolipid activator proteins (SAPs) and 
sphingomyelinase acid to lysosomes [19]. 
Under the effect of various stimuli such as a protein kinase (PKC)-dependent activator of 
metalloproteases, neurotensin (NT) receptor-3 (NTSR3) could be released from the plasma 
membrane by shedding producing the soluble form (sNTSR3) [20]. The sNTSR3 which is able 
by itself and upon binding to cells to stimulate Akt, Src and FAK phosphorylation thus can 
regulate intracellular pathways related to cell survival but not cell growth through its ability to 
bind and to be internalised in colon cancer cells [21]. Moreover, sNTSR3 plays a role in 
regulating the morphology of the cell, properties of cell-cell and the cell-matrix via reduction 
of integrins expression and modifying desmosomes structure resulting in initiation of cell 
separation and spreading leading to cancer metastasis [22]. While its role in CVD, DM and 
dyslipidaemia, a study found that levels of circulating sortilin associated with both CVD and 
DM when measuring the plasma sortilin levels from CVD and DM patients with higher levels 
of sortilin compared to the controls. Thus, sortilin levels could be used as a biomarker for CVD 
and DM, while validating these results further studies are required [23]. Another study 
demonstrated that activated platelet could release soluble sortilin upon collagen stimulation 
which act as a platelet stimulator, and this release can be suppressed by treatment with aspirin. 
They found that higher levels of sortilin in plasma were observed in patients having 
cardiovascular risk factors such as hypertension, dyslipidaemia and/or diabetes, hence high 
plasma soluble sortilin levels could be related to platelet activation and a risk factor for 
atherothrombosis in vivo [24]. In other studies, investigating circulating sortilin levels in type 
II DM patients with lower limb peripheral artery disease (PAD). Sortilin levels were found to 
be significantly high in this group and was independently associated with lower limb PAD and 
could be considered as a promising biomarker for atherosclerosis of the lower limb [25]. 
Gustafsen and colleagues found that PCSK9 secretion which is implicated in lipid metabolism 
is regulated by sortilin and there is a positive link between circulating PCSK9 and sortilin 
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whereby sortilin expression affects the circulating levels of PCSK9 in humans [9]. Another 
study investigated the relationship between serum sortilin levels and metabolic profiles of 
subjects newly diagnosed with type II DM and found the circulating levels of sortilin is lower 
in patients with newly diagnosed type II DM than in controls, also has a negative correlation 
with insulin resistance and undesirable lipid profiles, while a positive correlation with high-
density lipoprotein cholesterol in newly diagnosed type II DM subjects [26]. High serum 
sortilin levels found in patients with depression as explained by Buttenschøn et al., study and 
also found there is a link between the serum level of sortilin and BDNF in addition to vascular 
endothelial growth factor A (VEGF) which is a neurotrophic factor that has a role in depression 
pathophysiology [27]. 
There are several trafficking pathways for sortilin. Firstly, fusion of sortilin with the cell 
surface through the secretory vesicles, which is known as constitutive secretory pathway; at 
the cell surface, sortilin extracellular domain can be cleaved and released extracellularly; this 
represents about 5-10% of sortilin molecules, while the remaining intact sortilin functions as a 
ligand-binding site to transduce a signal or mediate endocytosis by AP2. Following the latter, 
the ligand may undergo lysosomal degradation while sortilin is transported back to the TGN 
with the help of retromer and AP1. Secondly, the anterograde sortilin transport which involves 
the movement of sortilin from TGN to early endosome by GGAs and AP1. Lysosomes usually 
degrade ligands and a portion of sortilin, while mainly sortilin is palmitoylated and transported 
reversely to TGN [28]. Thirdly, sortilin assists with ligand incorporation into secretory granules 
followed by extracellular signal stimulation in order to regulate the secretory pathway in cells 
[29]. 
Many studies have been performed to support the hypothesis that sortilin could be a protein 
sorting receptor, transporting ligands to the membrane surface, or between the Golgi and late 
endosomes through to endocytosis [2, 3, 30]. Thus, the physiological role of sortilin involves 
many different functions, including cell survival, induction of post-traumatic neuronal 
apoptosis, in addition to signal transduction, ligand-binding, and engaging in intracellular 
sorting. Also, sortilin mediates lipoprotein lipase, neurotensin and the pro-form of nerve growth 
factor (pro-NGF) endocytosis, transporting proteins from Golgi to the late endosomes, and act 
as a co-receptor with p75NTR on the cell membrane to induce neural death [19, 31, 32]. Also, 
sortilin has anti-apoptotic effects when it interacts with other neurotensin receptors; a study 
found that NTSR3/sortilin forms a functional complex with NTSR2 in pancreatic β-TC3 cells 
which is important to stimulate the protective role of neurotensin against apoptosis by Akt 
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activation [33]. Another study showed that human corneal keratocytes cultured with JMV449 
(pseudopeptide NT agonist) expressed NTSR1 and NTSR3, and JMV449 increased the cell 
proliferation and reduced apoptosis through NTRS1 along with NTRS3 which partially 
mediates the JMV449 effect on cell proliferation [34]. A study by da Silva et al., investigated 
the inflammatory response stimulated by lipopolysaccharide (LPS) in skin dendritic cells 
through NT effect, and they found that foetal-skin dendritic cells (FSDCs) expressed NTSR1 
and NTSR3 and treatment with LPS induces the expression of neurotensin which leads to 
downregulation of inflammatory signalling pathways NF-κB and JNK, and cytokines IL-6, 
TNF-α, IL-10 and vascular endothelial growth factor (VEGF) expression, while upregulating 
the ERK and epidermal growth factor (EGF) survival pathways [35]. Also, high sortilin 
expression found on the surface of B cell chronic lymphocytic leukaemia (B-CCL) than in 
healthy subjects and a correlation between sortilin and CD23 expression was also observed in 
leukemic cells suggesting that it is responsible for leukemogenesis of CCL cells, as a result 
sortilin could be used as a diagnostic and therapeutic biomarker for CCL patients [36]. 
 
Sortilin ligand binding sites 
Neurotensin (NT) is a tridecapeptide, firstly isolated from the hypothalamus of bovine in 1973 
and then from the small intestine [37], has both central and peripheral actions depending on its 
interaction with specific receptors on the plasma membrane of the targeted cells [2]. NT binds 
to three different receptors, neurotensin receptor 1 (NTSR1), NTSR2 and NTSR3 (sortilin). 
NTSR1 and 2 are seven-transmembrane G-protein coupled receptors, whereas NTSR3 or 
sortilin is a single transmembrane domain sorting receptor [38]. A study by Quistgaard and 
colleagues illustrated the 3D structure of sortilin and ligand binding sites. They found that the 
ectodomain structure of sortilin forms a complex with neurotensin through its C-terminal part 
in the tunnel of a ten-bladed β-propeller domain [39]. However, most ligands of Vps10p 
domain compete for binding which likely depends on steric hindrance rather than on identical 
binding sites, such as neurotensin act as a competitive inhibitor for most sortilin ligands. 
Furthermore, ten-bladed β-propeller of Vps10p domain has a fourfold increase in the volume 
of the tunnel and provide binding sites for an extended set of large protein ligands and only one 
ligand at a time as it confines the ligand binding to the tunnel rather than on an outer surface 
[40]. Moreover, the interaction with cell membrane or with transmembrane receptors, including 
p75NTR or TRKs family receptors has been proposed through two protruding hydrophobic 
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loops [39]. Another study used hydrogen/deuterium exchange mass spectrometry to examine 
sortilin conformational response when it binds to biological ligands, such as neurotensin, pro-
peptide of sortilin, progranulin, and pro-NGF and found that inside the sortilin β‐propeller 
tunnel, ligands have two binding sites and also progranulin and pro-NGF stabilise the residues 
in the 10CC-b domain [41]. 
 
Neurotrophin pathway 
Neurotrophins are a family of proteins required for vertebrate nervous system development, 
function and plasticity. Nerve growth factor (NGF) is the first characterised factor discovered 
during a search for survival factor; there are four neurotrophins, NGF, brain-derived growth 
factor (BDNF), neurotrophin-3 (NT-3), and neurotrophin-4 (NT-4). They are similar in their 
sequence and structure [42]. Initially, neurotrophins are synthesized as a precursor, which 
require cleavage to produce the mature protein. Their cleavage occurs inside the cell at the 
endoplasmic reticulum (ER) and Golgi by furin or pro-convertase at dibasic amino-acid 
cleavage site producing C-terminal mature neurotrophins [43]. While extracellular cleavage by 
the enzyme matrix metalloproteinase 7 (MMP-7) [44] or serine protease plasmin [45]. The 
amino terminal part of the precursor neurotrophins is important for neurotrophin folding [46] 
and sorting neurotrophins to either constitutive or regulated secretory pathways [45]. While the 
mature domains are the secreted ligands responsible for initiating the biological effects of 
neurotrophins [43]. 
Neurotrophins bind to specific receptors according to their affinities, nerve growth 
factor (NGF) binds to tropomyosin receptor A (TrkA); BDNF and neurotrophin 4 bind to 
tropomyosin receptor kinase B (TrkB); while neurotrophin 3 (NT3) to tropomyosin receptor 
kinase C (TrkC). However, the low affinity of binding NGF to TrkA, and of BDNF to TrkB, 
can be modified by dimerisation of the receptor, structural modification, and association with 
p75NTR receptor, which can also increase the ligand selectivity. The p75NTR receptor acts as a 
co-receptor for Trk receptors that can bind to each neurotrophin [47-49]. A study evaluated the 
selectivity and ability of proneurotrophins and mature neurotrophins binding to p75NTR and 
Trk receptors; they found that pro-NGF bound to p75NTR with an affinity of five times higher 
than mature NGF, this means that pro-NGF is the ligand of p75NTR not TrkA and p75NTR 
has more affinity to bind to pro-NGF than mature NGF to induce apoptosis [45]. Thus, the 
effect of neurotrophins on neuronal survival/death depends on if mature neurotrophins or pro-
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neurotrophins are secreted and bind to either Trk receptors or the complex p75NTR/sortilin to 
induce downstream signalling pathways [43]. P75NTR is a member of the tumour necrosis 
superfamily, consists of four cysteine-rich motifs in the extracellular domain, a transmembrane 
domain and a death domain in the cytoplasmic domain [50]. The extracellular domain contains 
four tandemly arranged domains for ligands binding followed by juxtamembrane stalk region 
of around 60 amino acids; the transmembrane domain has a sequence of 60 amino acids specific 
chopper module of p75 NTR that is connected to the death domain in the intracellular or 
cytoplasmic domain (Figure 1) [51]. Compared to the structure of Trk receptors, which contain 
the extracellular domain in which there is cysteine-rich cluster followed by three leucine-rich 
repeats, another cysteine-rich cluster and two immunoglobulin-like domains, transmembrane 
span ended with tyrosine kinase domain in the cytoplasm that have several tyrosines 
responsible for phosphorylation and act as docking sites for cytoplasmic adaptors and enzymes 
(Figure 1) [52].  
 Neurotrophins are involved in many different signalling pathways through interaction 
with two types of receptors on the cell surface (Trks and p75NTR) promoting survival, 




The interaction of tyrosine kinase receptors and ion channels has been discovered in many 
studies [53]. A study found that activation of TrkB receptor by BDNF in the rat olfactory bulb 
neurons uses Kv1.3 potassium channel as a substrate for the phosphorylation of tyrosine 
residue in the receptor and the function of this channel is altered depending on duration of 
trophic factor stimulation and previous odour sensory experience, this result applied for TrkB 
and have no effect on TrkA and TrkC as the majority of these receptors exist as truncated forms 
[54]. Another study found that binding of BDNF to TrkB can depolarise the membrane via 
rapid activation of tetrodotoxin (TTX)-insensitive sodium channel Nav 1.9 in HEK-293 cells 
[55]. There are many questions still unclear, such as the cellular mechanism and signalling 
cascades that are responsible for the modulation of ion channels by BDNF, understanding of 
the action of BDNF on ion channels, and the mode of ion channel activation; all these questions 
will add new insights to understanding the role of neurotrophins function in the brain. 
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Neurotrophin signalling pathway 
Ligand binding to extracellular part of tyrosine receptor kinases induces oligomerisation and 
autophosphorylation which represent the general mechanism for the growth factor and cell 
surface receptor activation [56]. Binding of neurotrophins to p75NTR and Trk family members 
is by the formation of dimers; dimerization of Trk receptor results in autophosphorylation and 
activation of intracellular signalling pathways [57]. The phosphorylated-tyrosines and the 
surrounding amino acid residues within the activated Trk molecule create binding sites for 
proteins having phosphotyrosine-binding (PTB) or Src homology 2 (SH2) domains. The Trk 
receptors activated pathways are Proto-Oncogene Proteins p21 (Ras), phosphatidylinositol 3-
kinase (PI3K), phospholipase C-γ1 (PLC-γ1), and their downstream effectors (Figure 2) [4]. 
 
Proto-Oncogene Proteins p21 (Ras) 
Ras activation is essential for the differentiation of neural cells and promotes many neural 
subpopulation survival. Neurotrophin (NGF) binds Trk receptor resulting in dimerization and 
autophosphorylation of the tyrosine residues [58]. For transient activation of Ras, the adaptor 
protein Src homology 2 domain-containing transforming protein 1 (Shc) links phosphor-Y490 
on Trk to another adaptor Growth factor receptor-bound protein 2 (Grb2) which in turn forms 
a complex with son of sevenless (SOS), a nucleotide exchange factor that functions to activate 
Ras by replacing GDP with GTP. Active Ras induces downstream signalling of PI3K and 
MAPK pathways [5]. For MAPK activation, active Ras interacts with the RAF proto-oncogene 
serine/threonine-protein kinase, which phosphorylates and activates Mitogen-activated ERK 
kinase (MEK) and MAP kinase isoforms. Finally, MAPK translocates to the nucleus, causing 
phosphorylation of transcription factors required for neural cell differentiation [58]. 
Termination of the signalling pathway is via phosphorylation of intermediates and activation 
of phosphatase, such as phosphorylation of SOS results in the SOS-Grb2 complex dissociation 
(Figure 2) [5].  
 
PI3K pathway 
PI3K pathway can be activated via Ras-dependent and independent pathways [5]. Ras-
dependant pathway depends on Shc phosphorylation by Trk that causes an increase in Ras 
activity and extracellular signal-regulated kinase (ERK) or known as MAP kinase, which in 
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turn induces transcriptional events, like cyclic adenosine monophosphate response element-
binding (CREB) transcription factor, that affects cell cycle, neurite outgrowth and synaptic 
plasticity [57]. While the Ras-independent pathway depends on recruiting GRB2-associated-
binding protein 1 (GAB1) via phosphorylated Grb2 initiating the subsequent activation of the 
PI3K signalling pathway [5]. The 3-phosphoinositides produced by PI3K activates two protein 
kinases, the serine-threonine kinase AKT and RAC-PK (Related to A and C protein kinase) 
[59]. AKT responsible for controlling the protein activities involved in promoting cell survival, 
such as substrates that control the caspase cascade, for example, Bcl-2-associated death 
promoter (BAD) (Figure 2) [60]. 
 
PLC-g pathway 
Also, PLC-γ binds to activated Trk receptors and induces an intracellular signalling cascade, 
leading to the production of inositol triphosphate (IP3) and diacylglycerol (DAG) by 
phosphatidylinositol 4,5-bisphosphate hydrolysis. IP3 stimulates mobilisation of cytoplasmic 
Ca2+ stores, while DAG regulates protein kinase C isoforms, both signalling molecules 
resulting in the activation of intracellular enzymes, such as protein kinase C isoforms and Ca2+- 
calmodulin-dependent protein kinases (Figure 2) [61]. 
 
EGFR pathway 
Epidermal growth factor (EGF) receptor belonging to the type I receptor tyrosine kinases of 
ErbB receptors and consists of extracellular domain (ECD), transmembrane segment, and 
intracellular domain (ICD) which has a tyrosine kinase domain [62]. Ligand binding to the 
ECD stimulates receptor dimerization and autophosphorylation at tyrosine residues of ICD to 
mediate various signalling pathways, such as RAS/RAF/MEK/ERK, PI3K/AKT/mTOR and 
JAK/STAT pathways that are involved in cell proliferation, survival, migration, invasion, anti-
apoptosis, and pro-angiogenesis. Termination of EGFR signalling is related to EGFR 
internalisation and degradation after binding to ligand, thus EGFR trafficking dysregulation 
participates in uncontrolled cell proliferation and survival such as in cancer cells [62, 63]. 
Following the study by Wilson’s group that illustrated sortilin plays a role in transporting and 
loading EGFR into extracellular vesicles by endocytosis [64], another study showed that 
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sortilin regulates EGFR internalisation and limiting the proliferative signalling, thus loss of 
sortilin promotes continuous EGFR signalling and accelerates tumor growth in vivo [65]. 
 
Cell survival versus cell death 
Sortilin binds TrkA, -B, and -C to facilitate the anterograde axonal transport of these receptors 
and thus enhance the signalling of neurotrophins; and sortilin is a positive modulator of 
neuronal survival induced by neurotrophins [66]. In TGN, sortilin interacts with Trk receptors 
to shuttle them to the nerve terminals along the axonal path where they can form a 
heterodimeric complex with p75NTR and transduce mature NTs signals [67]. The p75 NTR 
receptor signalling pathway involves the activation of NF-κB and Jun N-terminal kinase (JNK) 
and modulates RhoA activity. These are initiated by binding of adaptor proteins to the 
cytoplasmic domain of p75 NTR, such as neurotrophin-receptor interacting factor (NRIF), 
neurotrophin-associated cell death executor (NADE), neurotrophin-receptor-interacting 
MAGE homologue (NRAGE), Schwann cell 1 (SC1), and receptor-interacting protein 2 
(RIP2), which have effects on apoptosis and non-apoptotic or survival response [68, 69]. 
Apoptosis pathway involves the formation of the sortilin complex with p75NTR, which in turn 
binds with high affinity to pro-neurotrophins [70]. The interaction takes place in the 
extracellular domain of sortilin and p75 NTR to form a heterodimer that is strengthened by the 
pro-neurotrophin ligands, while the intracellular domain has no role in this interaction; the 
intracellular domain of sortilin plays a role in regulating the cleavage rate of p75 NTR through 
its regulatory function in p75-regulated intramembrane proteolysis and apoptosis [51], whereas 
binding of neurotrophins to p75 NTR activates Jun kinase-signalling cascade resulting in the 
activation of p53 and apoptosis and also promotes Fas ligand expression resulting in apoptosis 
through Fas receptor. Activation of NF-κB has a role in neural survival; neurotrophins initiates 
the signalling through the association of TNF receptor-associated factor 6 (TRAF6) to p75NTR 
cytoplasmic domain, after recruitment of several kinases the transcription factor NF-κB 
released. While Rho activity controls growth cone motility (Figure 2) [5]. Pro-neurotrophins 
are ligands that bind selectively to the p75 NTR compared to the mature form and are more 
effective at inducing apoptosis by their interaction to p75 NTR [45], thereby the regulation of 
biological function of neurotrophins is by their proteolytic cleavage, with the mature forms 
activating the Trk receptor and inducing cell survival and the pro-forms activate p75 NTR to 
promote apoptosis. 
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Sortilin and human diseases 
The discovery of sortilin in 1997 illustrated the physiological function of the protein. The 
modification in its expression can lead to the development of several human diseases in both 
the central and peripheral organs [8]. Sortilin has a role in neurological disorders, such as 
Alzheimer’s and Parkinson’s diseases; it also affects lipid and glucose homeostasis regulation. 
In cancer, sortilin is dysregulated in different cancer types. As sortilin controls the trafficking 
of neurotrophins and acts as a receptor or co-receptor. Thus, any defect in this regulation and 




• Alzheimer’s diseases (AD) 
Alzheimer’s disease (AD) is the most common neurodegenerative disease. According to the 
WHO report in 2016, the number of people affected with AD is about 46.8 million in the world, 
and the number is expected to be double to 74.7 million by 2030 [71]. It is caused by tangles 
and senile plaques accumulation, that leads to neuronal loss in the hippocampus region of the 
brain. Senile plaques consist of amyloid-β peptides, which come from the two proteolytic 
enzymes action on β-amyloid precursor protein (APP), known as β- and γ- secretase.  APP is 
firstly cleaved by β-secretase-amyloid precursor protein-cleaving enzyme 1 (BACE1), 
accompanied by γ-secretase to produce amyloid peptides and an intracellular fragment [7, 72]. 
Some studies found that the over-expression of sortilin (not other VPS10p receptors, like 
sorLA) tend to be high in the post-mortem brains of patients [73, 74], while another study did 
not discover that the sortilin expression is significantly changed in AD [75]. Saadipour and 
colleagues illustrated that Aβ42 presence in culture media is enough to increase the expression 
levels of both mRNA and protein of sortilin mediated through p75NTR in SH-SY5Y cells in a 
time and dose-dependent manner [74]. However, the sortilin cytoplasmic domain can regulate 
BACE1 subcellular distribution, and thus affect the proteolytic process of APP mediated by 
BACE1, which facilitates retrograde transport of the enzyme. In addition, sortilin over-
expression correlates with increased cleavage of APP by BACE1 through the interaction of 
BACE1 with sortilin at the TGN [73]. 
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Moreover, sortilin ectodomain proteolysis is mediated by transmembrane metalloprotease A 
disintegrin and metalloproteinase domain-containing protein 10 (ADAM10) separating the 
ligand-binding domain from the trafficking motifs encoded by intracellular domain, and sortilin 
shedding can occur at the cell surface and intracellularly. The significant biological role of this 
cleavage is unclear, a study demonstrated that the cytoplasmic tail of sortilin interacts with pro-
domain of brain-derived neurotrophic factor (BDNF) to facilitate the trafficking of BDNF 
through the secretory pathway [76]. The cleavage of sortilin ectodomain by A disintegrin and 
metalloproteinase domain-containing protein 10 (ADAM10) represents the regulatory switch 
for BDNF delivery to either the secretory pathway or to the lysosome [77]. A study from Fleitas 
and colleagues, implicates pro-BDNF neurotoxic signalling in AD pathology primarily by three 
mechanisms: one is increased expression of p75NTR and sortilin [78] while the others are 
increased p75 basal levels processing found in AD, and increased stability of proBDNF by 
post-translational modification induced by reactive oxygen species (ROS). They studied 
BDNF, pro-BDNF and their receptors’ relative levels and found there is a significant increase 
of sortilin and pro-BDNF in the hippocampus. In AD pro-BDNF-p75/sortilin signalling 
contribute to the pathogenesis and increase in cell death with neural differentiation impairment. 
The reactive oxygen species (ROS) induced glycation end products to cause pro-BDNF 
modification, which prevents pro-BDNF from maturing and increases the pathogenicity [78]. 
A recent report showed that the levels of full-length sortilin were increased in the neocortical 
lysates from aged and AD cases that is relative to middle-aged cases [79]. In this study, they 
characterised the full length sortilin normal expression pattern in adult human cerebrum by 
using two antibodies binding the extracellular and intracellular domains, and they found that 
there were extracellular deposits of sortilin C-terminal antibody in the human brains with 
cerebral amyloid pathology, these deposits present as mini-plaques, densely packed and mature 
looking plaques with a ring-like shape, these deposits are fragments with 15kDa and are 
elevated in the cortical lysates from the human brains of AD accompanied with amyloid 
pathology compared to aged/mid-age controls [79].	
Another study found clusterin (CLU) is one of the genes contributing to the risk of a late-onset 
type of AD (LOAD); also it is heat shock family member that is highly conserved and 
participates in physiological processes, such as cell cycle, apoptosis, and adhesion, 
inflammation, lipid transport and membrane recycling. Clusterin binds to Aβ, prevent the 
aggregation of Aβ and promote their lysosomal degradation. Also, they found that the 
expression of sortilin increased with a reduction in clusterin level due to Aβ 1-42 treatment in 
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primary hippocampal neurons in the rat and M17 neuroblastoma cells of human. Sortilin binds 
clusterin and targeting it to lysosomal degradation, thereby, knockdown of sortilin prevents 
clusterin degradation by Aβ induction [80]. 
AD also, characterised by propagated prions (misfolded tau proteins). Johnson et al. (2017) 
found that formation and histopathologic deposition of tau prion is highly confined to the 
hindbrain [81]. They used prion propagation assay and found that tau prion replication inhibited 
by inhibitors derived from forebrain such as sortilin. This inhibition is mediated through sortilin 
interaction with prion protein and direct it to the lysosomes for degradation and knockdown of 
sortilin accelerates prion disease. Sortilin plays a role in neuroprotection and in the presence of 
sortilin prevents the replication of tau prion and can be considered as a therapeutic target in 
tau-related disease [81]. 
In addition, other Vps10p members are being challenged in drug discovery, such as SorL1 for 
AD therapy [82]. A component of ginger called 6-shogaol has neuronal cell anti-inflammatory 
and antioxidant effects. This has been investigated to see whether 6-shogaol increases the levels 
of sortilin-related receptor 1 (SORL1) which is a neural sorting protein responsible for reducing 
the trafficking of amyloid precursor protein (APP) and thus prevent the generation of Aβ. They 
found that inhibiting SORL1 by siRNA results in an increase in BACE, secreted APP-β 
(sAPPβ) and Aβ. While, SORL1 activated via 6-shogaol and significantly downregulate 
BACE, sAPPβ and Aβ both in vitro and in vivo [82]. Further studies are required to elucidate 
the role of sortilin in AD pathogenesis and as well as the development of new therapies for the 
treatment of this devastating disease.   
 
Parkinson’s Disease (PD) 
PD is a common neurodegenerative disease that occurs commonly in the elderly population 
and rare before 50 years old, with an incidence ranges from 5 to over 35 new cases per 100,000 
cases every year worldwide [83]. PD is caused by progressive impairment and death of 
dopaminergic neurons in the substantia nigra. Both Lewy bodies and Lewy neuritis are the 
hallmarks of PD that consist of aggregated alpha-synuclein (α-syn) found in assemblies of 
fibrillar protein in neural cells [84, 85]. Szego et al. (2013) showed that gene expression of 
NGF and TrkA was upregulated in wild type mice treated with 1-methyl 4-phenyl-1,2,3,6-
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tetrahydropyridine hydrochloride (MPTP), in contrast, sortilin and p75NTR genes were 
upregulated in the A30P α-synuclein-expressed mice [86]. 
Diabetes mellitus (DM) 
Diabetes mellitus (DM) is a metabolic disorder, classified into type I and type II. DM is 
characterised by chronic hyperglycaemia, with an incidence of about 415 million people 
worldwide, 90% of cases had type II DM mainly in low- and middle- income countries [87], 
and causes death of around 1.6 million people in 2016 [88]. Type I DM is juvenile-onset 
diabetes, caused by T-cell mediated attack on the beta cells of the pancreas that produce insulin, 
with a worldwide estimate of 542,000 affected children in 2015 [89]. Type II DM is the most 
common and is caused by insulin resistance with partial insulin deficiency, associated with 
ageing, obesity and physical inactivity [90]. 
In adipocytes, sortilin colocalised with glucose transporter type 4 (GLUT4) and is one 
of the major proteins in the GLUT4 storage vesicles. Sorting protein sortilin is responsible for 
the formation of insulin-responsive GLUT4 storage vesicles in adipocytes and myocytes to 
stimulate the insulin-regulated glucose uptake. Thus, the decrease in sortilin levels may prevent 
the trafficking and secretion of GLUT4 which could be linked to type II DM. However, further 
studies are required to establish the role of sortilin in type II DM [91, 92]. The defect in glucose 
transport is likely to be correlated with insulin resistance and modulation of sortilin expression 
levels in obesity and diabetes [93]. In addition, they found that the TNF-α controls the sortilin 
expression in adipose tissues and low-grade inflammatory state in obesity that could contribute 
to insulin resistance [93]. A study has found that regulating NT and sortilin have reduced the 
chance of developing obesity, metabolic disorders and hepatic steatosis, which could be an 
exciting avenue to target in therapy [94]. Sortilin facilitates the trafficking of acid 
sphingomyelinase (aSMase) to the cell surface, resulting in metabolic changes in diet-induced 
obesity (DIO) and sortilin knockdown promotes insulin signalling in adipose tissue with a 
reduction in acid sphingomyelinase (aSMase) activity end with attenuation of hepatic steatosis 
and inflammation [94].  
On the other hand, a large precursor that is responsible for the synthesis of neurotensin 
(NT) and contains a six amino acid NT-like peptide known as neuromedin N (NN). The C-
terminal region of the precursor (pro-NT/NN) contains NT and NN separated by three Lys-Arg 
sequences. However, depending on the tissue that express the precursor the three Lys-Arg sites 
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are differentially processed to give rise to NT and NN [95]. A study showed the relation of 
plasma pro-neurotensin levels and the risk of developing diabetes among populations from 
Middle East and Caucasus [96]. They found that plasma pro-neurotensin levels are higher in 
Middle Eastern than Caucasian populations and effects the glucose control, thus this suggests 
that pro-neurotensin could be a type II diabetes strong determinant in populations from Middle 
East  compared to Caucasian populations [96]. Another study showed there is a significant 
relation between fasting pro-neurotensin and developing diabetes, cardiovascular disease, and 
breast cancer in women. This study concluded that there is an interaction between sex and pro-
neurotensin while confirmation of this phenomena still need further experiments to study the 
same outcome on men [97]. 
 
Cardiovascular Disease 
Cardiovascular disease (CVD) is the leading cause to morbidity and mortality in Western 
countries, with an incidence of about 17.9 million people die every year, which represents 31% 
of all global death [98]. CVD involves the heart and/or blood vessels. Age, genetics, sex, 
smoking habits, diabetes, hypertension and hypercholesterolemia are the common risk factors 
that can contribute to developing CVD. Advances in technologies gave rise to next generation 
sequencing (NGS) which paved the way for Genome-Wide Association Studies (GWAS) of 
population-based cohorts [99-102]. Functional roles of sortilin in CVD, studied using NGS 
data, suggest that high expression of sortilin leads to increased LDL internalisation by reducing 
plasma level [103, 104] and transcriptional regulation of sortilin expression and LDL 
concentration in the circulation through CCAAT/enhancer-binding protein (C/EBPα) [105]. 
Recently, a study demonstrated that sortilin colocalised with proprotein convertase 
subtilisin/Kexin type 9 (PCSK9), a variant implicated in lipid metabolism in the TGN and 
causes its secretion from hepatocytes. As a result, sortilin expression mirrors PCSK9 plasma 
level and overexpression of sortilin confer high plasma PCSK9 [9]. 
Moreover, GWAS has helped to reveal the association between CVD and sortilin by finding 
out novel candidate genes or loci responsible for the cardiac phenotypes. A gene cluster, 
CELSR2-PSRC1-MYBPHL-SORT1 at loci 1p13.3 has many single nucleotide polymorphisms 
which may, in turn, affect the normal function of proteins and are associated with CVD. The 
intergenic region between PSRC1 and CELSR2 and downstream of SORT1 and MYBPHL has 
all the single-nucleotide polymorphisms. Where SORT1 encodes sortilin, PSRC1 encodes 
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proline/serine-rich coiled-coil protein 1, MYBPHL encodes myosin-binding protein H like and 
CELSR2 encodes cadherin EGF LAG (epidermal growth factor laminin A G-type) seven-pass 
G-type receptor 2. These studies help to use sortilin as a cardiovascular risk marker and as a 
potential drug target [106, 107]. Other studies based on ethnicity; demonstrated by whole 
genome sequence and lipoprotein (a) Lp(a) which is a risk factor for CVD with different 
concentrations in African and European ancestry. They found that genetic determinants have 
many unique determinants between Europeans and Africans, and the lipoprotein(a) Lp(a) 
rs12740374 a common variant independent of LDL cholesterol is the expression quantitative 
trait loci (eQTL) for SORT1. Both African and European people have up to 90% Lp(a) 
heritability by twin studies, and its concentration is linked to atherosclerotic CVD. Thus, Lp(a) 
can be used as a promising target in the treatment of CVD [108]. 
In addition, sortilin has a role in glucose and lipid metabolism regulation. Thus, any defect can 
lead to atherosclerosis and obesity. To study this role, a study showed that female mouse model 
with a deficiency in both low-density lipoprotein receptor (Ldlr- / -) and sortilin (Sort1-/-) causes 
suppression of Niemann-Pick type C1-Like 1 (NPC1L1) mRNA levels; NPC1L1 a protein 
responsible for the absorption of intestinal cholesterol [109]. This suppression causes a 
decrease in body weight and white adipose tissue, which store lipid and improves the function 
of brown adipose tissue that takes part in energy expenditure and lipid metabolism via partial 
downregulation of the transcription of Kruppel-like factor 4 and liver X receptor [109].  
 
Other Diseases  
α-1 antitrypsin deficiency (α1ATD) 
α1ATD is a genetic disorder that leads to the accumulation of abnormal α1AT protein in liver 
cells due to a decrease in the activity of α-1 antitrypsin in the blood and lungs. The incidence 
of the disease in Europe is about 1 in 600 and 1 in 2000 individuals, while between 1 in 3000 
and 1 in 6000 individuals in the USA [110, 111]. It is caused by a mutation that gives rise to 
the Z variant of AT (α1ATZ) and creates a defect in folding and secretion. As α1ATZ builds 
up in the liver, it aggregates and accumulates in the liver, and at the same time leads to a 
decrease in α1AT in the lungs [112]. However, the severity of ATZ-associated liver disease 
could be altered by modification of sortilin levels; a study demonstrated that ATZ after being 
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routed from TGN is degraded in the vacuole, and sortilin acts as a receptor that can deliver the 
aberrant proteins to the vacuole [113]. 
 
Lysosomal storage disease (LSD)  
LSD is an inborn error of metabolism, affecting the normal function of the lysosome. Mutations 
in the lysosomal protein-encoding genes cause LSD by affecting the integrity of lysosomal 
glycosidases, proteases, transporters, integral membrane proteins, and modifiers or activator 
enzymes [114]. Globally LSD has an incidence of 1 in 7000 to 1 in 8000 live births [115]. 
Mutations produce malfunctioned proteins, which in turn cause the accumulation of substrates 
in the lysosome and result in cellular dysfunction and death [114]. The standard LSD 
classification includes storage molecules like sphingolipidoses, mucopolysaccharidoses and 
glycoproteinosis and recently updated with lysosomal membrane proteins, activator proteins, 
transport proteins and non-lysosomal proteins [116]. 
Lysosomes are vesicles containing digestive enzymes, like glucosidases, proteases, and 
sulfatases. The ER is responsible for the synthesis of lysosomal enzymes that are transported 
to the Golgi apparatus then directed to lysosomes by the addition of mannose-6-phosphate label 
[115]. Sortilin plays a role in the mannose-6-phosphate independent pathway and binds to 
various ligands, such as neurotensin and receptor-associated protein (RAP). Sortilin mediates 
trafficking of proteins, like sphingolipid activator proteins including prosaposin and GM2 
activator proteins, acid sphingomyelinase, cathepsins D and H, to lysosomes [19, 117-119]. 
However, the most recent therapeutic approaches for LSD are enzyme replacement therapy, 
gene therapy or hematopoietic stem cell transplantation, pharmacologic chaperone for 
defective enzyme stabilisation or substrate reduction therapy [116]. 
 
Cancer 
Sortilin, one of Vps10p sorting receptor family members, is involved in several roles, including 
intracellular protein transport and as a co-receptor. Sortilin interacts with the neurotrophin Trk 
receptors (Trk-A, -B, and -C) and enhances their signalling pathways. Therefore, a defect in 
sortilin expression effects neurotrophin signalling pathways and could contribute to the 
development of different types of cancer. However, deregulation of sortilin expression has been 
studied in several carcinomas such as breast, colorectal, thyroid, lung, and glioblastoma.  




Breast cancer is the most common cause of death among women, with a chance of about 1 in 
4 cancer cases among women and about 2.1 million cases were diagnosed in females in 2018 
[120]. Most breast cancer cells growth and maintenance dependant on oestrogen hormones. 
Breast cancer is divided into three major subtypes due to the presence or absence of molecular 
markers for the oestrogen or progesterone receptor and human epidermal growth factor 2 
(ERBB2; previously known as HER2). Approximately, 70% of patients are hormone receptor 
(HER2) negative, 15-20% are (HER2) positive, and 15% are triple-negative, all markers are 
absent [121]. Tamoxifen is the selective oestrogen receptor modulator, which until now used 
as a standard therapy; also, oestrogen receptor pathway correlates with human epidermal 
growth factor receptor (HER2) pathway with about 22% of HER2 is overexpressed in breast 
cancer [122]. 
Several studies have shown that sortilin participates in breast cancer cells invasion [123, 124]. 
Pro-NGF dependent autocrine signalling is mediated by overexpressed TrkA and sortilin, 
activating Akt and Src, in breast cancer cell invasion. [123]. In addition, NGF promotes breast 
cancer cell proliferation with less expressed TrkA and overexpressed P185HER2 [125]. 
Moreover, progression of breast carcinoma from a primary tumour to pleural effusion is 
mediated by overexpressed phospho-Trk-A receptor (activated receptor) [126].  
Progranulin is an 88-kDa secreted glycoprotein cleaved by neutrophil elastase and matrix 
metallopeptidase 12 (MMP12) to produce biologically active 6-kDa granulin peptide domain 
[127]. Progranulin acts on differentiated cells that express sortilin and initiate tumour 
progression partially by triggering dedifferentiation and increasing the cancer stem cell pool 
proliferation. Thus, inhibition of sortilin blocks the propagation induction by progranulin in the 
breast cancer stem cells and prevent metastasis and infiltration [127]. On the other hand, EphA2 
was identified, which is a membrane receptor tyrosine kinase through a study on proteins 
interacting with TrkA upon pro-NGF stimulation [128]. In breast cancer cells, signaling 
through sortilin and TrkA by pro-NGF binding recruits EphA2, which in turn causes Src 
activation in a TrkA phosphorylation-independent manner. As an assumption, 
proNGF/TrkA/EphA2 axis can be used both as a marker for diagnosis and target for therapy. 
[128]. Zhang and colleagues studied TrkA signalling pathway because of its role in the 
proliferation of breast cancer cells that are resistant to chemotherapy [129]. They found that 
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knockdown of TrkA by small interference RNA (siRNA) results in the inhibition of cancer cell 
proliferation and cell cycle arrest at G0/G1 phase through NF-κB p65 inactivation and induces 
apoptosis through activation of caspase-3. Thereby, to enhance breast cancer’s chemotherapy 
effectiveness, TrkA pathway inhibition could be a potential pharmacologic target [129].  
 
Colorectal Cancer (CRC) 
Colorectal Cancer (CRC) is the third cancer-related deaths worldwide [130]. CRC incidence is 
steadily increasing in the world, particularly in developing countries with an incidence of about 
2 million new cases and 1 million deaths expected in 2018 [131]. Many risk factors are 
associated with the development of CRC, including age and hereditary factors, while 
environmental and lifestyle are modifiable factors heavily contributing to the high incidence of 
the disease [132]. Many tyrosine kinase receptors, such as epidermal growth factor receptor 
(EGFR), vascular EGFR and tropomyosin-related kinase B (TrkB), are involved in the 
initiation, progression and metastasis of CRC. TrkB is overexpressed in tumorous compared to 
non-tumorous tissues and correlate with the density and metastasis to the lymphatic vessels 
[133]. The BDNF and its receptor TrkB, are also overexpressed in colorectal cancer cell lines 
and BDNF expression and release are increased by blockage of a gastrin-releasing peptide by 
EGFR-dependant mechanism [134].  
In contrast, it has been suggested that TrkB function is to protect CRC cells from anoikis in the 
circulatory and lymphatic systems [135]. A study explained the pathway involved in the 
development of CRCs through the phosphorylation of Akt via the upstream phosphorylation 
of the complex focal adhesion kinase and steroid receptor coactivator (FAK-Src) by small 
concentrations of soluble sortilin (10nM). This pathway regulates several downstream 
intracellular pathways responsible for cell migration and proliferation [136]. Stress culture 
conditions enhance autocrine secretion of BDNF and relocate TrkB to the cell surface of the 
CRC cells, which is a major mechanism in cancer cell survival [137]. As a result, BDNF and 
TrkB are important for the growth of CRC cells in vitro and in tumours. In another study the 
dual inhibition of TrkB/BDNF and autophagy pathways reduces the tumour volume followed 
by long term treatment and thus can be considered as a new therapeutic approach for CRC 
[138]. 
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Thyroid Cancer (TC) 
Thyroid cancer (TC) causes around 567,000 cases, with an incidence rate of 10.2 per 100,000 
women around the world, which means it is three times higher in women than men, and ranking 
in ninth place [120]. The follicular or papillary variants (differentiated thyroid cancer) 
comprises over 90% of thyroid cancers [139]. It is suggested that hormonal factors play a role 
in the aetiology of thyroid cancer [140, 141]. Furthermore, studies showed that thyroid-
stimulating hormone (TSH) may be involved in the development of thyroid carcinomas, with 
epidemiological evidence that smoking, and alcohol consumption may be inversely associated 
with the production of TSH [142, 143]. 
In thyroid cancer, the pro-NGF is overexpressed and suggests the role in pathogenesis 
[144]. However, there is no clear status of NGF/pro-NGF receptors in thyroid tissue. A study 
explained that pro-NGF binds to the complex of sortilin-p75NTR receptor and initiates several 
signalling pathways, such as NF-κB, RhoA, and JNK. Also, neurotrophin tyrosine receptor 
kinase 1 (NTRK1 or TrkA) activated by pro-NGF [145]. Targeting overexpressed TrkA, 
sortilin and p75NTR in thyroid cancers resulted in growth and invasion reduction, which could 
be used as a therapeutic target [146].  
 
Lung Cancer  
Lung cancer is the leading cause of cancer-related mortality worldwide, with about 2.1 million 
cases and 1.8 million deaths reported in 2018, which represents around 18.4% cancer deaths 
[120]. There are two histological types of lung cancer, small cell lung cancer (SCLC) and non-
small cell lung cancer (NSCLC). NSCLC represents about 85% of all lung cancer cases, with 
common subtypes named adenocarcinoma and squamous cell carcinoma [147]. Cigarette 
smoking is the common cause of lung cancer [148, 149] and is responsible for over 40% of 
deaths from lung diseases such as cancer according to WHO. Also, cumulated exposure to air 
pollution can cause lung cancer as an adverse effect to this exposure. Also, exposure to 
carcinogens leads to increased risk of lung and other cancers [150, 151]. Genetic factors may 
contribute to developing lung cancer by gene mutation, and those with one copy of the mutated 
gene have 30% risk of developing cancer, compared to around 70% in those with two copies 
[152-154].  
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Tyrosine kinase receptors, such as EGFR, transmit information into the cell from the 
microenvironment thereby activating the relevant signalling pathways and inducing cell 
proliferation. Sortilin has an important role in the communication between the NSCLC and 
endothelial cells through exosomes. This is achieved through the interaction of sortilin with 
two tyrosine kinase receptors (TrkB and EGFR) called the TES complex, which is found inside 
lung cancer exosomes. The TES-containing lung cancer exosomes were shown to control cell 
migration and activate angiogenesis [64]. Sortilin was also shown to regulate EGFR 
internalisation and loss of sortilin in tumour cells induced the proliferation by maintaining 
EGFR signalling at the cell surface [65].  A study on the expression of NGF, pro-NGF, TrkA, 
sortilin and p75NTR in a series of lung cancers compared to normal lung tissues demonstrated 
that the expression of NGF, pro-NGF increased in squamous cell carcinoma and 
adenocarcinoma and TrkA in squamous cell carcinoma, while p75NTR was increased in all lung 
cancer types, compared to sortilin which was shown to be highly expressed in adenocarcinoma 
and small cell carcinoma. This implies that targeting NGF-TrkA axis in squamous cell 
carcinomas can be used for therapeutic effects [155]. On the other hand, TrkB can be used as 
a therapeutic target in metastatic lung adenocarcinoma as explained [156]. In this study, they 
found that TrkB expression is directly upregulated by hypoxia-inducible factor-1α [156]. The 
data suggest that TrkB drives migration via partial activation of Akt signalling and its 
knockdown in human lung cancer cells decreases migration and metastasis significantly [156]. 
NTRK2 gene encodes two isoforms, TrkB-FL which is a full-length receptor responsible for 
the regulation of several pathways related to cancer, and TrkB-T1 which is a truncated form 
having a different cytoplasmic domain encoded in a unique 3’ terminal exon of the mRNA. A 
study demonstrated that the most abundant mRNA is TrkB-T1 in oral, laryngeal, oesophageal 
and lung squamous cell carcinoma examined compared to normal cell types. TrkB-FL binds 
BDNF and activates different signalling pathways such as the PI3K/AKT pathway, 
ERK/MAPK pathway, and phospholipase C pathway. While the TrKB-T1 isoform can form 
heterodimers with the active forms of kinase and act as dominant-negative of TrkB-FL, also 
can compete for BDNF, and alter the proliferation and survival phenotypes of neural cells 
[157].  
The oncogenic driver neurotrophin receptor kinase (NTRK) gene fusions (NTRK+) are rare 
but present in solid tumours such as lung cancer. NTRK family consists of three members 
(NTRK1, NTRK2, NTRK3). A large number of Chinese lung cancer patients were screened 
over three years and they were found positive for NTRK1 fusions and other genetic alterations 
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that coexisted with NTRK1 fusions, such as mutations in tumour suppressor genes Tp53, 
neurofibromin (NF1), and retinoblastoma (RB1) [158]. It was concluded that NTRK1+ lung 
cancer accounts about 0.1% of NSCLC cases, and one half of NTRK+ NSCLC cases has a 
resistance mechanism to EGFR tyrosine kinase inhibitors (TKIs) regardless of which 
generation of EGFT TKIs used. This study did not characterise NTRK2/3 fusions, thus study 
of NTRK2/3 will be important to assess in future studies [158]. 
 
Glioblastoma multiforme (GBM) 
The most common and deadly type; affecting adult males with 40% cases progressing from a 
lower-grade brain tumour to the malignant type, while the remaining 60% are de novo [159, 
160]. Also, it represents stage IV of gliomas and considered as the most aggressive type with 
the median survival time being 15 months, even after treatment with chemotherapy, 
radiotherapy and surgical procedures [161]. GBM is the most aggressive primary malignant 
brain tumour with an incidence of less than 10 per 100,000 people globally and accounts for 
60% of brain tumours in adults [162]. Also, it is the third cancer-causing death with 2.5% 
deaths between the ages of 15 to 35 years [163]. 
The aetiology of brain cancers still not fully understood, and they are highly incurable. The 
expected carcinogenetic cause is the exposure to high ionizing radiation dose. At the same time, 
there is no conclusive effect of environmental factors like, smoking, cell phones, 
electromagnetic field, severe head injury, and diets with GBM initiation [164]. Several studies 
explained the role of neurotrophins and their receptors for glioma invasion and proliferation 
[165, 166]. Neurotrophins have been predicted to promote tumour growth. Singer and 
colleagues have demonstrated NGF treatment stimulates cell proliferation of glioblastoma cell 
lines, as well as enhancing the secretory pathway of NGF [167]. Another study demonstrated 
the relationship between the expression of neurotrophin receptors and YKL-40 expression 
(YKL-40 abbreviation derived from the first three N-terminal amino acids code, tyrosine (Y), 
lysine (K), and leucine (L) with the molecular weight) in the cells, which plays a role in the 
progression and aggressiveness of glioblastoma. YKL-40, is one of the mammalian chitinase-
like glycoprotein family members, encoded by CHI3L1 gene, and has a role in GBM cell 
migration, survival, invasion and angiogenesis. Silencing of YKL-40 in U87-MG cells results 
in the reduction of TrkB, sortilin and P75NTR expressions, and thus a decrease in GBM 
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aggressiveness [168]. Another study proved that sortilin level correlates with GBM 
aggressiveness and poor prognosis. Also, promotes glioblastoma invasion and mesenchymal 
transition through Glycogen Synthase Kinase 3 beta (GSK-3β)/ β-catenin/ Twist pathway 
[169]. Tong et al., investigated p75NTR expression and regulation in hypoxic glioma cells in 
vivo and in vitro [170]. They found that p75NTR regulates the glioma aggressiveness in hypoxia, 
such as migration, invasion and stemness [170]. The expression and protein levels of p75NTR 
are upregulated in primary hypoxic human glioma cells. The p75NTR stabilizes hypoxia 
inducing factors (HIF-α, HIF-β).  Knockdown of p75NTR results in a decrease of expression of 
both HIF-α and HIF-β at hypoxia. While knocking down of one of HIFs did not affect the 
p75NTR level, this explains that p75NTR is the regulator of hypoxic response of glioma cells and 
thereby can be represented as a target to treat brain tumors [170]. 
 
Targeting neurotrophins for the treatment of disease 
The imbalance in neurotrophin signalling characterising neurodegenerative diseases suggests 
that activation of Trk receptors using agonists or blocking the effect of p75NTR through 
antagonists represent a promising therapeutic approach. However, clinical trials utilising 
exogenous neurotrophin agonists have failed due to poor pharmacokinetic and 
pharmacodynamic properties as well as unintended targeting of p75NTR [171]. In Alzheimer's 
disease, a β-turn peptidomimetic (D3) which acts as TrkA agonist and stimulates dimerization 
and phosphorylation of the receptor [172]; also was showed an improvement in learning and 
short term-memory when tested on Alzheimer's mouse module [173]. A natural product 
Gambogic amide activates TrkA by kainic acid and decreases neural death [174]. Whereas, 
Paecilomycine A [175] and Deoxygedunin [176] has TrkB agonist's effect that induces 
neurogenesis and neural survival, respectively. Also, Deoxygedunin has a neuroprotective 
effect when studied in Parkinson's disease animal models [177]. Moreover, competitive ligands 
with pro-NGF and NGF on their binding to p75NTR could lead to neuroprotection; such ligands 
are LM11A-24, and LM11A-31 have been tested on Alzheimer's disease mouse model [178]. 
Variations in the expression and activity of Trk receptors such as NTRK gene 
alterations and fusions are considered as cancer drivers; therefore clinical trials are ongoing to 
test pan-TRK inhibitors that target TrkA, -B, and -C on several cancer types [179, 180]. Efforts 
in developing a more specific sortilin inhibitor (A38469) which could be utilised in the study 
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of sortilin function and its role in disease [181]. A recent study in Western diet (WD)-fed mice 
showed that using SORT1 inhibitor (AF38469) by oral route reduces the plasma cholesterol 
level and provides evidence that it could be used as a pharmacological target to treat 
dyslipidaemia [182]. On the other hand, ongoing clinical trial studying the effect of AL001, 
which is a recombinant human anti-human SORT1 monoclonal IgG1 antibody has an FDA 
orphan drug designation to treat frontotemporal dementia. It is designed to target GRN 
mutations, thus could increase the progranulin level in the plasma and cerebrospinal fluid 
(CSF) in a dose-dependent manner [183, 184]. Another study based on conjugating a cytotoxic 
drug to peptide ligands that can selectively bind an exclusively expressed receptor on cancerous 
cells. They used conjugated Doxorubicin to a sortilin binding peptide (KA-peptide) in ES-2 
and SKOV-3 ovarian cancer cell line models [185]. This study paves the way to use 
personalised therapy in the treatment of cancers through targeting sortilin [183]. 
  
Conclusion and future perspective: 
Herein, we have explored the connections between the neurotrophin pathway and sortilin 
function in a number of life-threatening human diseases. Sortilin is a Vps10p domain receptor 
present inside the cell or on the cell surface encompassing different roles in the cell as a 
receptor, co-receptor or protein transporter in the secretory pathway. The interaction of sortilin 
with neurotrophins through tyrosine receptor kinases and p75 initiate signals for cell survival 
and apoptosis respectively. A common denominator is that the neurotrophins pathway are 
linked to signalling pathways including the EGFR pathway by cross-talk between three major 
MAPK pathways and PI3K/AKT survival pathway. Interestingly, sortilin interacts with 
EGFR/and or TrkB and traffics these co-receptors to the nucleus or are secreted from the cell 
as exosomes for cellular communication. The function and expression of sortilin is finely tuned 
to facilitate normal physiological processes and thus an imbalance may promote the 
development of many human diseases such as AD, CVD, type II DM and cancer. The 
expression of sortilin at the transcript and protein level is closely regulated in the different 
human diseases with strong evidence of a genetic risk and direct association. To note, the 
monitoring of sortilin levels in the circulation could be a useful biomarker for the presence of 
diseases such as CVD and type II DM. Targeting the neurotrophins pathway could provide a 
promising route to combat a number of human diseases such as neurodegeneration and cancer. 
With this endeavour, a number of potential therapeutic strategies are emerging into the clinic. 
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There is hope that these drug discovery strategies will challenge the role of neurotrophins in 
human disease. Still, the ideal therapeutics would correct the imbalance or dysregulation of the 
neurotrophin pathway. Further studies are required to understand the cellular mechanism of 
sortilin and neurotrophins in normal versus disease progression and to determine specific active 
molecules that can be targeted in the site of action avoiding other tissues. 
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Figure legends 
Figure 1 Neurotrophins and their tyrosine receptor kinases (Trks) and p75NTR. The 
precursor form of neurotrophins (pro-NGF, pro-BDNF, proNT-3, and proNT-4) interact with 
high affinity to p75NTR). After cleavage, the mature form neurotrophin NGF interacts with a 
high affinity to TrkA, BDNF and NT-4 to TrkB, and NT-3 to TrkC. Sortilin forms a complex 
with p75NTR and induces cell death upon proneurotrophins binding, while the complex that 
involve Trk receptors is included in cell survival pathways.  CR1-CR4 cysteine-rich motif; 
C1/C2 cysteine-rich clusters; LRR1-3 leucine-rich repeats; Ig1/Ig2 immunoglobulin-like 
domains. 
 
Figure 2 Neurotrophins signalling. This illustrates neurotrophin interaction with Trk, sortilin 
and p75 receptors, and the main intracellular signalling pathways activated through these 
receptors. The p75 receptor regulates three different pathways. Neurotrophins interaction with 
p75NTR activates NF-κB pathway that induces cell survival by TRAF6 association with 
p75NTR cytoplasmic domain and activation of IκB kinase (IKK) that phosphorylates and 
degrades IκB proteins to liberate NF-κB to enter the nucleus. While Jun kinase pathway 
promotes cell apoptosis through the activation of Jun kinase cascade followed by downstream 
activation JUN kinase (JNK) which in turn activates P53 and Bax that induces apoptosis, also 
phosphorylates c-JUN that translocates to nucleus while Rho activation controls growth cone 
motility. As mentioned in the text, interaction of p75 with sortilin and pro-neurotrophins 
stimulate pro-apoptotic action through JNK apoptotic pathway. The Trk receptor also 
stimulates three signalling pathways by forming complex with p75NTR and interact with 
neurotrophins. MAP Kinase signalling pathway induces cell differentiation by recruiting Shc 
that promotes Grb2-SOS complex formation which in turn recruits Ras and stimulates MAPK 
pathway, PI3K promotes cell survival and growth through GAB1 recruitment by 
phosphorylated Grb2 to activate protein kinase Akt control other proteins important in cell 
survival. PLC-γ activation results in calcium activation by IP3 and PKC by DAG, which both 
control synaptic plasticity.  
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